Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Real-World, Retrospective Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The aim of this retrospective study was to evaluate the efficacy of adjuvant cisplatin-based chemotherapy in patients with locally advanced upper tract urothelial carcinoma (UTUC), administered following radical nephroureterectomy. Materials and Methods Patients with UTUC, arising from renal pelvis or ureter, staged pT3/T4 or N+ were treated with adjuvant chemotherapy following surgery. The chemotherapy consisted of gemcitabine 1,000 mg/m2 on days 1 and 8, cisplatin 70 mg/m2 on day 1. Treatment was repeated every 3 weeks for up to 4 cycles. Endpoints included disease-free survival (DFS), metastasis-free survival (MFS), and safety. Results Among 89 eligible patients, 85 (95.5%) completed at least 3 cycles of adjuvant chemotherapy. Chemotherapy was well tolerated, the main toxicities being mild-to-moderate gastrointestinal toxic effects and pruritus. With a median follow-up of 37 months, median DFS was 30 months (95% confidence interval, 22 to 39), and the median MFS was not reached. The 3-year DFS and MFS were 44% and 56%, respectively. Multivariate analyses revealed that the main factor associated with DFS and MFS was the lymph node involvement, whereas age, T category, grade, or the primary site of UTUC were not significantly associated with DFS or MFS. Conclusion Adjuvant cisplatin-based chemotherapy after radical surgery of pT3/T4 or N+ UTUC was feasible and may demonstrate benefits in DFS and MFS. Whether novel agents added to the chemotherapy regimen, as a concurrent combination or maintenance, impacts on survival or reduces the development of metastases remains to be studied.
Abstract
Purpose The aim of this retrospective study was to evaluate the efficacy of adjuvant cisplatin-based chemotherapy in patients with locally advanced upper tract urothelial carcinoma (UTUC), administered following radical nephroureterectomy. Materials and Methods Patients with UTUC, arising from renal pelvis or ureter, staged pT3/T4 or N+ were treated with adjuvant chemotherapy following surgery. The chemotherapy consisted of gemcitabine 1,000 mg/m2 on days 1 and 8, cisplatin 70 mg/m2 on day 1. Treatment was repeated every 3 weeks for up to 4 cycles. Endpoints included disease-free survival (DFS), metastasis-free survival (MFS), and safety. Results Among 89 eligible patients, 85 (95.5%) completed at least 3 cycles of adjuvant chemotherapy. Chemotherapy was well tolerated, the main toxicities being mild-to-moderate gastrointestinal toxic effects and pruritus. With a median follow-up of 37 months, median DFS was 30 months (95% confidence interval, 22 to 39), and the median MFS was not reached. The 3-year DFS and MFS were 44% and 56%, respectively. Multivariate analyses revealed that the main factor associated with DFS and MFS was the lymph node involvement, whereas age, T category, grade, or the primary site of UTUC were not significantly associated with DFS or MFS. Conclusion Adjuvant cisplatin-based chemotherapy after radical surgery of pT3/T4 or N+ UTUC was feasible and may demonstrate benefits in DFS and MFS. Whether novel agents added to the chemotherapy regimen, as a concurrent combination or maintenance, impacts on survival or reduces the development of metastases remains to be studied.
참고문헌 (20)
- David KA, "Surveillance of urothelial carcinoma : stage and grade migration, 1993-2005 and survival trends, 1993-2000", Cancer, 115, pp.1435~1447 (2009)
- Lee JY, "Molecular characterization of urothelial carcinoma of the bladder and upper urinary tract", Transl Oncol, 11, pp.37~42 (2018)
- Birtle A, "Adjuvant chemotherapy in upper tract urothelial carcinoma(the POUT trial) : a phase 3, open-label, randomised controlled trial", Lancet, 395, pp.1268~1277 (2020)
- Bajorin DF, "Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma", N Engl J Med, 384, pp.2102~2114 (2021)
- Galsky MD, "Extended follow-up results from the CheckMate 274 trial", J Clin Oncol, 41(6 Suppl), pp.LBA443~ (2023)
- Tae JH, "Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma : a nationwide cohort study", BMC Urol, 22, pp.175~ (2022)
- Munoz JJ, "Upper tract urothelial neoplasms : incidence and survival during the last 2 decades", J Urol, 164, pp.1523~1525 (2000)
- Babjuk M, "EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder", Eur Urol, 54, pp.303~314 (2008)
- Hall MC, "Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract : a 30-year experience in 252 patients", Urology, 52, pp.594~601 (1998)
- Advanced Bladder Cancer Meta-analysis Collaboration, "Neoadjuvant chemotherapy in invasive bladder cancer : update of a systematic review and meta-analysis of individual patient data advanced bladder cancer(ABC)meta-analysis collaboration", Eur Urol, 48, pp.202~205 (2005)
- Moussa S, "Outcome of surgical treatment of patients with upper versus lower urinary tract urothelial carcinoma : stage-by-stage comparison", Urol Int, 84, pp.50~55 (2010)
- Rink M, "Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery", Eur Urol, 62, pp.677~684 (2012)
- Gupta R, "Neoplasms of the upper urinary tract : a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting", Adv Anat Pathol, 15, pp.127~139 (2008)
- Lughezzani G, "Prognostic factors in upper urinary tract urothelial carcinomas : a comprehensive review of the current literature", Eur Urol, 62, pp.100~114 (2012)
- Stein JP, "Radical cystectomy in the treatment of invasive bladder cancer : long-term results in 1, 054 patients", J Clin Oncol, 19, pp.666~675 (2001)
- Shariat SF, "Clinical nodal staging scores for bladder cancer : a proposal for preoperative risk assessment", Eur Urol, 61, pp.237~242 (2012)
- Roscigno M, "Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer", Eur Urol, 60, pp.776~783 (2011)
- Roscigno M, "Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy", J Urol, 181, pp.2482~2489 (2009)
- Roscigno M, "The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma : how many lymph nodes should be removed?", Eur Urol, 56, pp.512~518 (2009)
- Powles T, "Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma", N Engl J Med, 383, pp.1218~1230 (2020)